PL421576A1 - Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK - Google Patents

Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK

Info

Publication number
PL421576A1
PL421576A1 PL421576A PL42157617A PL421576A1 PL 421576 A1 PL421576 A1 PL 421576A1 PL 421576 A PL421576 A PL 421576A PL 42157617 A PL42157617 A PL 42157617A PL 421576 A1 PL421576 A1 PL 421576A1
Authority
PL
Poland
Prior art keywords
group
alkyl
pyrazolo
pyrimidine
inhibitors
Prior art date
Application number
PL421576A
Other languages
English (en)
Other versions
PL233595B1 (pl
Inventor
Bartosz STYPIK
Michał Mroczkiewicz
Anna BUJAK
Krzysztof SZYMCZAK
Paweł Gunerka
Krzysztof DUBIEL
Maciej Wieczorek
Jerzy Pieczykolan
Original Assignee
Celon Pharma Spolka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma Spolka Akcyjna filed Critical Celon Pharma Spolka Akcyjna
Priority to PL421576A priority Critical patent/PL233595B1/pl
Priority to US16/609,891 priority patent/US11072619B2/en
Priority to MX2019013462A priority patent/MX392641B/es
Priority to PT187235320T priority patent/PT3621966T/pt
Priority to KR1020197034120A priority patent/KR102533519B1/ko
Priority to BR112019023480-2A priority patent/BR112019023480B1/pt
Priority to CN201880030939.9A priority patent/CN110612302B/zh
Priority to HRP20210021TT priority patent/HRP20210021T1/hr
Priority to AU2018265457A priority patent/AU2018265457B2/en
Priority to JP2019562296A priority patent/JP7157084B2/ja
Priority to PCT/EP2018/062164 priority patent/WO2018206739A1/en
Priority to DK18723532.0T priority patent/DK3621966T3/da
Priority to HUE18723532A priority patent/HUE052997T2/hu
Priority to PL18723532T priority patent/PL3621966T3/pl
Priority to ES18723532T priority patent/ES2845230T3/es
Priority to CA3059829A priority patent/CA3059829A1/en
Priority to EP18723532.0A priority patent/EP3621966B1/en
Priority to EA201992632A priority patent/EA038273B1/ru
Priority to SI201830179T priority patent/SI3621966T1/sl
Publication of PL421576A1 publication Critical patent/PL421576A1/pl
Publication of PL233595B1 publication Critical patent/PL233595B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Przedmiotem zgłoszenia jest związek o wzorze ogólnym (I), w którym R1 oznacza fenyl podstawiony jednym lub dwoma podstawnikami wybranymi z grupy składającej się z halogenu i alkoksylu C1-C3; 5- lub 6-członowy heteroaryl, który zawiera 1 lub 2 atomy N, niepodstawiony lub podstawiony podstawnikiem wybranym z grupy składającej się z -NH2, halogenu, alkilu C1-C4, dihalogenoalkilu C1-C4, alkoksylu C1-C3, 6-członowego heterocyklilu, który zawiera 1 lub 2 heteroatomy wybrane z grupy składającej się z N i O, i (6-członowy heterocyklilo)-(C1-C4)-alkilu, gdzie heterocyklil zawiera 1 lub 2 heteroatomy wybrane z grupy składającej się z N i O; lub 9-członowy bicykliczny heteroaryl, który zawiera 2 atomy N, podstawiony alkilem C1-C4, oraz jego sole addycyjne z kwasami. Związek znajduje zastosowanie jako lek w leczeniu przewlekłych chorób zapalnych i autoimmunologicznych.
PL421576A 2017-05-12 2017-05-12 Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK PL233595B1 (pl)

Priority Applications (19)

Application Number Priority Date Filing Date Title
PL421576A PL233595B1 (pl) 2017-05-12 2017-05-12 Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK
US16/609,891 US11072619B2 (en) 2017-05-12 2018-05-10 Pyrazole[1,5-a] pyrimidine derivatives as kinase JAK inhibitors
MX2019013462A MX392641B (es) 2017-05-12 2018-05-10 Derivados de pirazolo[1,5-a]pirimidina como inhibidores de cinasas janus (jak)
PT187235320T PT3621966T (pt) 2017-05-12 2018-05-10 Derivados de pirazole[1,5-a]pirimidina como inibidores de cinase jak
KR1020197034120A KR102533519B1 (ko) 2017-05-12 2018-05-10 키나아제 jak 저해제로서 피라졸[1,5-a]피리미딘 유도체
BR112019023480-2A BR112019023480B1 (pt) 2017-05-12 2018-05-10 DERIVADOS DE PIRAZOLO [1,5 -a] PIRIMIDINA COMO INIBIDORES DE QUINASE JACK
CN201880030939.9A CN110612302B (zh) 2017-05-12 2018-05-10 作为激酶JAK抑制剂的吡唑并[1,5-a]嘧啶衍生物
HRP20210021TT HRP20210021T1 (hr) 2017-05-12 2018-05-10 Derivati pirazol[1,5-a]pirimidina kao inhibitori jak kinaze
AU2018265457A AU2018265457B2 (en) 2017-05-12 2018-05-10 Pyrazole(1,5-a)pyrimidine derivatives as kinase JAK inhibitors
JP2019562296A JP7157084B2 (ja) 2017-05-12 2018-05-10 キナーゼＪＡＫ阻害剤としてのピラゾロ［１，５－ａ］ピリミジン誘導体
PCT/EP2018/062164 WO2018206739A1 (en) 2017-05-12 2018-05-10 Pyrazole[1,5-a]pyrimidine derivatives as kinase jak inhibitors
DK18723532.0T DK3621966T3 (da) 2017-05-12 2018-05-10 Pyrazol[1,5-a]pyrimidinderivater som kinase jak-inhibitorer
HUE18723532A HUE052997T2 (hu) 2017-05-12 2018-05-10 JAK kináz inhibitor pirazol[1,5-a]pirimidin származékok
PL18723532T PL3621966T3 (pl) 2017-05-12 2018-05-10 Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK
ES18723532T ES2845230T3 (es) 2017-05-12 2018-05-10 Derivados de pirazol[1,5-a]pirimidina como inhibidores de quinasa JAK
CA3059829A CA3059829A1 (en) 2017-05-12 2018-05-10 Pyrazolo[1,5-a]pyrimidine derivatives as kinase jak inhibitors
EP18723532.0A EP3621966B1 (en) 2017-05-12 2018-05-10 Pyrazole[1,5-a]pyrimidine derivatives as kinase jak inhibitors
EA201992632A EA038273B1 (ru) 2017-05-12 2018-05-10 Производные пиразоло[1,5-a]пиримидина в качестве ингибиторов киназы jak
SI201830179T SI3621966T1 (sl) 2017-05-12 2018-05-10 Derivati pirazol(1,5-A)pirimidina kot kinazni JAK inhibitorji

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL421576A PL233595B1 (pl) 2017-05-12 2017-05-12 Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK

Publications (2)

Publication Number Publication Date
PL421576A1 true PL421576A1 (pl) 2018-11-19
PL233595B1 PL233595B1 (pl) 2019-11-29

Family

ID=64104351

Family Applications (2)

Application Number Title Priority Date Filing Date
PL421576A PL233595B1 (pl) 2017-05-12 2017-05-12 Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK
PL18723532T PL3621966T3 (pl) 2017-05-12 2018-05-10 Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18723532T PL3621966T3 (pl) 2017-05-12 2018-05-10 Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK

Country Status (17)

Country Link
US (1) US11072619B2 (pl)
EP (1) EP3621966B1 (pl)
JP (1) JP7157084B2 (pl)
KR (1) KR102533519B1 (pl)
CN (1) CN110612302B (pl)
AU (1) AU2018265457B2 (pl)
CA (1) CA3059829A1 (pl)
DK (1) DK3621966T3 (pl)
EA (1) EA038273B1 (pl)
ES (1) ES2845230T3 (pl)
HR (1) HRP20210021T1 (pl)
HU (1) HUE052997T2 (pl)
MX (1) MX392641B (pl)
PL (2) PL233595B1 (pl)
PT (1) PT3621966T (pl)
SI (1) SI3621966T1 (pl)
WO (1) WO2018206739A1 (pl)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022561A1 (en) * 2002-09-04 2004-03-18 Schering Corporation Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
EP1725235B1 (en) 2004-02-05 2009-04-15 Schering Corporation Piperidine derivatives useful as ccr3 antagonists
ATE482213T1 (de) * 2004-11-04 2010-10-15 Vertex Pharma Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
EP2123651A4 (en) 2007-01-12 2011-05-04 Astellas Pharma Inc CONDENSED PYRIDINE COMPOUND
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
RU2012107101A (ru) 2009-07-31 2013-09-10 Байокрист Фармасьютикалз, Инк. Производные пирроло[1,2-в] пиридазина как ингибиторы янус-киназы
US9242987B2 (en) * 2009-10-20 2016-01-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
US8921368B2 (en) 2011-03-17 2014-12-30 Bristol-Myers Squibb Company Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
AR085435A1 (es) * 2011-03-17 2013-10-02 Bristol Myers Squibb Co Inhibidores de pirrolopiridazina jak3 y su uso para el tratamiento de enfermedades inflamatorias y autoinmunes
UA111854C2 (uk) * 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
ES2666353T3 (es) 2012-09-06 2018-05-04 Bristol-Myers Squibb Company Inhibidores de JAK3 de imidazopiridazina y su uso para el tratamiento de enfermedades inflamatorias y autoinmunitarias
PL407081A1 (pl) * 2014-02-05 2015-08-17 Celon Pharma Spółka Akcyjna Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK-2

Also Published As

Publication number Publication date
KR102533519B1 (ko) 2023-05-17
MX2019013462A (es) 2020-01-15
US11072619B2 (en) 2021-07-27
ES2845230T3 (es) 2021-07-26
AU2018265457A1 (en) 2019-10-24
JP7157084B2 (ja) 2022-10-19
WO2018206739A1 (en) 2018-11-15
CN110612302A (zh) 2019-12-24
AU2018265457B2 (en) 2022-06-30
EP3621966A1 (en) 2020-03-18
EA038273B1 (ru) 2021-08-03
SI3621966T1 (sl) 2021-04-30
BR112019023480A2 (pt) 2020-06-30
EA201992632A1 (ru) 2020-04-13
PT3621966T (pt) 2021-01-20
DK3621966T3 (da) 2021-01-18
KR20200005562A (ko) 2020-01-15
PL233595B1 (pl) 2019-11-29
EP3621966B1 (en) 2020-11-18
CA3059829A1 (en) 2018-11-15
PL3621966T3 (pl) 2021-06-28
JP2020519631A (ja) 2020-07-02
HUE052997T2 (hu) 2021-06-28
CN110612302B (zh) 2022-06-14
US20200199128A1 (en) 2020-06-25
MX392641B (es) 2025-03-24
HRP20210021T1 (hr) 2021-02-19

Similar Documents

Publication Publication Date Title
EA202191104A1 (ru) Производные аминопиридина/пиразина в качестве ингибиторов ctps1
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
PH12018500437B1 (en) Novel pyrazolo [3,4-d] pyrimidine compounds or salt thereof
EA202091475A1 (ru) ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
SA520411638B1 (ar) Tam أملاح لمشتقات بيرولو ترايازين مفيدة كمثبطات لـ
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
PE20150218A1 (es) Nuevos derivados fosfatos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
MX2017004129A (es) Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2- il)amino-benzoico como inhibidor de quinasa p38.
PE20160115A1 (es) Compuestos derivados de imidazol como inhibidores de protein quinasa
UA116768C2 (uk) Дизаміщені бензотієнілпіролотриазини та їх застосування як інгібіторів кінази рфрф
IL283368B1 (en) An imidazo[1,2-b]pyridazin-7-yl-urea compound and a medicine comprising the compound
EA201591906A1 (ru) Производные мочевины, полезные в качестве ингибиторов киназы
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
MX2018002885A (es) Sales de inhibidor de pim cinasa.
ZA202106014B (en) Solid forms of condensed pyrazines as syk inhibitors
PL408251A1 (pl) Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
EA201892020A1 (ru) Индольные производные и их применение в качестве ингибиторов протеинкиназы
PL407081A1 (pl) Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK-2
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
PL411864A1 (pl) Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy P13
EA201791743A1 (ru) Производные имидазо[2,1-в]тиазола и 5,6-дигидроимидазо[2,1-в]тиазола, применяемые в качестве s100-ингибиторов
PL421576A1 (pl) Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK